3D Visualization of the Dynamic Bidirectional Talk Between ER/PR and Her2 Pathways

Background: Extensive amounts of archived formalin fixed paraffin embedded (FFPE) human tumor tissues are the ultimate resource to investigate signaling network underlying tumorigenesis in human. Yet, their usage is severely limited for lacking of suitable protein techniques. In this study, a quantitative, objective, absolute, and high throughput immunoblot method, quantitative dot blot (QDB), was explored to address this issue by investigating the putative relationship between estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2) pathways in breast cancer tumorigenesis. Methods: In this descriptive observational retrospective study, ER, PR, Her2, and Ki67 protein levels were measured absolutely and quantitatively in 852 FFPE breast cancer tissues using the QDB method. ER, PR, and Her2 levels were charted on the X, Y, and Z-axes to observe samples distribution in a 3D scatterplot. Results: A “seesaw” relationship between ER/PR and Her2 pathways was observed in ER–PR–Her2 space, characterized by the expression levels of these 3 proteins. Specimens with strong expressions of ER/PR proteins were found spreading along the ER/PR floor while those with strong Her2 expression were found wrapping around the Her2 axis. Those lacking strong expressions of all 3 proteins were found accumulating at the intersection of the ER, PR, and Her2 axes. Few specimens floated in the ER–PR–Her2 space to suggest the lack of co-expression of all 3 proteins simultaneously. Ki67 levels were found to be significantly reduced in specimens spreading in the ER–PR space. Conclusions: The unique distribution of specimens in ER–PR–Her2 space prior to any clinical intervention provided visual support of bidirectional talk between ER/PR and Her2 pathways in breast cancer specimens. Clinical interventions to suppress these 2 pathways alternatively warrant further exploration for breast cancer patients accordingly. Our study also demonstrated that the QDB method is an effective tool to analyze archived FFPE cancer specimens in biomedical research.

1. Yu, G, Zhang, W, Zhang, Y, et al. Developing a routine lab test for absolute quantification of HER2 in FFPE breast cancer tissues using quantitative Dot blot (QDB) method. Sci Rep. 2020;10(1):12502. doi:
10.1038/s41598-020-69471-4.
Google Scholar | Crossref | Medline2. DeSouza, LV, Siu, KWM. Mass spectrometry-based quantification. Clin Biochem. 2013;46(6):421-431. doi:10.1016/j.clinbiochem.2012.10.025.
Google Scholar | Crossref | Medline3. Boellner, S, Becker, K-F. Reverse phase protein arrays-quantitative assessment of multiple biomarkers in biopsies for clinical Use. Microarrays Basel Switz. 2015;4(2):98-114. doi:10.3390/microarrays4020098.
Google Scholar | Crossref | Medline4. Tian, G, Tang, F, Yang, C, et al. Quantitative dot blot analysis (QDB), a versatile high throughput immunoblot method. Oncotarget. 2017;8(35):58553-58562. doi:10.18632/oncotarget.17236.
Google Scholar | Crossref | Medline5. Zhang, W, Yu, G, Zhang, Y, et al. Quantitative Dot blot (QDB) as a universal platform for absolute quantification of tissue biomarkers. Anal Biochem. July 1, 2019;576(1):42-47. doi:10.1016/j.ab.2019.04.003.
Google Scholar | Crossref | Medline6. Hao, J, Lyu, Y, Zou, J, et al. Improving prognosis of surrogate assay for breast cancer patients by absolute quantitation of Ki67 protein levels using quantitative Dot blot (QDB) method. Front Oncol. September 17, 2021;11:3673. doi:10.3389/fonc.2021.737781.
Google Scholar | Crossref7. Goldhirsch, A, Winer, EP, Coates, AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206-2223. doi:10.1093/annonc/mdt303.
Google Scholar | Crossref | Medline | ISI8. Arpino, G, Wiechmann, L, Osborne, CK, Schiff, R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008;29(2):217-233. doi:10.1210/er.2006-0045.
Google Scholar | Crossref | Medline | ISI9. Giuliano, M, Trivedi, MV, Schiff, R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care. 2013;8(4):256-262. doi:10.1159/000354253.
Google Scholar | Crossref | Medline10. Montemurro, F, Di Cosimo, S, Arpino, G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. Ann Oncol. 2013;24(11):2715-2724. doi:10.1093/annonc/mdt287.
Google Scholar | Crossref | Medline11. Giuliano, M, Hu, H, Wang, Y-C, et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(17):3995-4003. doi:10.1158/1078-0432.CCR-14-2728.
Google Scholar | Crossref | Medline | ISI12. Collins, D, Jacob, W, Cejalvo, JM, et al. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. PLOS ONE. 2017;12(5):e0177331. doi:10.1371/journal.pone.0177331.
Google Scholar | Crossref | Medline13. von Elm, E, Altman, DG, Egger, M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-. doi:10.7326/0003-4819-147-8-200710160-00010.
Google Scholar | Crossref | Medline | ISI14. Wolff, AC, Hammond, MEH, Schwartz, JN, et al. American Society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2007;26(1):118-145. doi:10.1200/JCO.2006.09.2775.
Google Scholar | Crossref15. Dowsett, M, Nielsen, TO, A’Hern, R, et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. JNCI J Natl Cancer Inst. 2011;103(22):1656-1664. doi:10.1093/jnci/djr393.
Google Scholar | Crossref16. Konecny, G, Pauletti, G, Pegram, M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. JNCI J Natl Cancer Inst. 2003;95(2):142-153. doi:10.1093/jnci/95.2.142
Google Scholar | Crossref17. Wolff, AC, Hammond, MEH, Hicks, DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. doi:10.1200/JCO.2013.50.9984.
Google Scholar | Crossref | Medline | ISI18. Wolff, AC, Hammond, MEH, Allison, KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. May 30, 2018;36(20):2105–2122. doi:10.1200/JCO.2018.77.8738.
Google Scholar | Crossref | Medline19. Zhang, J, Yang, M. Developing a growing cancer profile database based on quantitative analysis of protein biomarkers in formalin-fixed paraffin-embedded specimens. Future Oncol Lond Engl. 2020;16(31):2471-2474. doi:10.2217/fon-2020-0480.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif